DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION
Loading...
  • Stocks
  • /
  • Pharmaceuticals & Biotech
Updated 2y ago
ERV2 logo

Molecule Holdings Inc.DB:ERV2 Stock Report

Market Cap €330.8k
Updated 2y ago
Share Price
n/a
1Y-92.9%
7D0%
1D0%
Portfolio Value
​
View

Molecule Holdings Inc.

DB:ERV2 Stock Report

Market Cap: €330.8k

  • Company Overview
    • Valuation
    • Future Growth
    • Past Performance
    • Financial Health
    • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

Molecule Holdings (ERV2) Stock Overview

Manufactures and sells cannabis-infused beverages in Canada. More details

ERV2 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Negative shareholders equity

Earnings have declined by 20.4% per year over past 5 years

Does not have a meaningful market cap (€489K)

Shares are highly illiquid

+ 1 more risk

ERV2 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW423,602 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
423,602 investors already sharing narratives
€
Current Price
€0.000598.0% undervalued intrinsic discount
%/yr
Decrease
Increase
PastFuture-6m2m2016201920222025202620282031Revenue CA$1.8mEarnings CA$264.0k
Advanced
View all narratives

Molecule Holdings Inc. Competitors

TFF Pharmaceuticals

Symbol: MUN:0K30
Market cap: €9.7m

Cantourage Group

Symbol: XTRA:HIGH
Market cap: €68.6m

Biofrontera

Symbol: XTRA:B8FK
Market cap: €14.6m

Hemo Organic

Symbol: BSE:524590
Market cap: ₹68.8m

Price History & Performance

Summary of share price highs, lows and changes for Molecule Holdings
Historical stock prices
Current Share PriceCA$0.0005
52 Week HighCA$0.02
52 Week LowCA$0.0005
Beta-0.78
1 Month Change0%
3 Month Change0%
1 Year Change-92.86%
3 Year Change-99.26%
5 Year Changen/a
Change since IPO-98.87%

Recent News & Updates

Recent updates

Shareholder Returns

ERV2DE PharmaceuticalsDE Market
7D0%-0.7%-0.6%
1Y-92.9%41.5%4.9%

Return vs Industry: ERV2 underperformed the German Pharmaceuticals industry which returned -19.5% over the past year.

Return vs Market: ERV2 underperformed the German Market which returned 3.2% over the past year.

Price Volatility

Is ERV2's price volatile compared to industry and market?
ERV2 volatility
ERV2 Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement4.9%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.8%
10% least volatile stocks in DE Market2.5%

Stable Share Price: ERV2 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ERV2's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aDavid Reingoldmolecule.ca

Molecule Holdings Inc. engages in production and co-packing of cannabis-infused beverages in Canada. It also offers cannabis extracts, beverages, edibles, and topical products directly to provincial retailers. The company offers its beverage products under the PHRESH, KLÕN, EMBODY, and CANAJO brands.

Molecule Holdings Inc. Fundamentals Summary

How do Molecule Holdings's earnings and revenue compare to its market cap?
ERV2 fundamental statistics
Market cap€330.75k
Earnings (TTM)-€3.45m
Revenue (TTM)€1.78m
0.0x
P/S Ratio
0.0x
P/E Ratio

Is ERV2 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ERV2 income statement (TTM)
RevenueCA$1.78m
Cost of RevenueCA$2.23m
Gross Profit-CA$449.70k
Other ExpensesCA$3.01m
Earnings-CA$3.45m

Last Reported Earnings

Jul 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.035
Gross Margin-25.27%
Net Profit Margin-194.18%
Debt/Equity Ratio-102.3%

How did ERV2 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/02 09:16
End of Day Share Price 2024/03/06 00:00
Earnings2023/07/31
Annual Earnings2022/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Molecule Holdings Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide